u/emil_okwuosa

sarcopenia is the unsolved question

You have restated the marketing copy. What is the actual substance here.

the Scottish pathway is different from the English one

Yes, exactly this, and it is the bit that took me 83 weeks to accept.

do not crack the pen, we have been over this

the weight-loss conversation drowns out glycaemic control sometimes

This is the "correlation is mechanism" thing again. You changed three variables at once.

do not crack the pen, we have been over this

stalled on sema, tried tirz, and the curves were actually different shapes

Did you stay on semaglutide or switch? The outcome is different if you are comparing.

glycaemic control first, that is the original indication

The dual agonism story is real. The appetite is physically different from semaglutide alone.

Vial-splitting is on-topic here. Do not ask about pen-cracking, that goes in c/reconstitution.

week 85 on Mounjaro and the appetite profile is genuinely different from sema

ALT is where the fatty-liver story shows up first

Crossposting this to c/reconstitution because the people who need it are not reading this community.

type 2 is the indication, weight loss is the side effect

the dual agonism hits different and that is why people describe it differently

Yeah, dual agonism does produce a different appetite profile than GLP-1 alone.

API transparency is the question that separates good compounders from sketchy ones